NL – Accardrine – AC 262

10mg | 50 Tabs

SKU: NL000130 Category:

Nova Labs Accardine (AC-262) is a selective androgen receptor modulator (SARM) designed for users seeking lean muscle growth, improved recovery, and enhanced athletic performance without the significant androgenic effects associated with traditional anabolic agents. AC-262 has gained popularity for its mild anabolic activity, making it suitable for those looking for moderate muscle gains and endurance improvements.

Benefits

  • Lean Muscle Growth: AC-262 selectively targets androgen receptors, promoting muscle growth and strength gains without intense androgenic side effects.
  • Enhanced Recovery and Endurance: It supports muscle recovery and endurance, allowing for improved performance during physical activities.
  • Minimal Hormonal Impact: Unlike stronger SARMs, AC-262 is less likely to cause hormonal disruptions, making it appealing for users concerned about testosterone suppression.

Suggested Dosage

  • AC-262: 10-20 mg per day, typically taken in cycles of 6-8 weeks for optimal results.

For best practices and minimizing potential side effects, consult a healthcare professional to tailor dosages to individual needs.

Potential Side Effects

  • Mild Suppression: AC-262 has a lower likelihood of testosterone suppression but may still require post-cycle therapy (PCT) if used in higher doses or longer cycles.
  • Mood Changes: A few users report mild mood swings or irritability, which may be due to hormonal changes.
  • Headaches or Digestive Discomfort: Occasionally, users may experience mild headaches or digestive upset, especially during the first week of use.

Nova Labs Accardine (AC-262) is a balanced option for those looking for moderate muscle-building benefits and endurance improvements with minimal androgenic and hormonal impact, making it ideal for beginners and intermediate users seeking performance enhancement.

Reviews

There are no reviews yet.

Be the first to review “NL – Accardrine – AC 262”

Your email address will not be published. Required fields are marked *

Scroll to Top